11 completed. 11 Phase 4.
By phase and status
Follow Bp Consulting, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
Xibrom, Nevanac - Intraocular Pressure | Phase 4 | Completed | Bp Consulting, Inc | 25 | 2009-01-01 | 2009-06-10 |
Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.
Bromefenac, Blink - Diabetic Macular Edema | Phase 4 | Completed | Bp Consulting, Inc | 50 | 2008-08-01 | 2009-09-04 |
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
Bromfenac, Moxifloxacin hydrochloride, Prednisolone Acetate - Cataracts | Phase 4 | Completed | Bp Consulting, Inc | 49 | 2008-07-01 | 2012-03-15 |
Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
Xibrom, and Optive, Xibrom and Pred Forte - Cataracts | Phase 4 | Completed | Bp Consulting, Inc | 200 | 2008-06-01 | 2009-06-10 |
Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
Istalol and Optive, Alphagan - Ocular Hypertension, Open-Angle Glaucoma | Phase 4 | Completed | Bp Consulting, Inc | 40 | 2008-06-01 | 2008-12-04 |
Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses
New PEG based artificial tear, Optive - Comfort, Vision and Wear Time | Phase 4 | Completed | Bp Consulting, Inc | 50 | 2008-03-01 | 2010-02-22 |
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality
PEG-400 based artificial tear, Systane - Dry Eye | Phase 4 | Completed | Bp Consulting, Inc | 70 | 2008-02-01 | 2010-02-03 |
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).
PEG- 400 based artificial tear, Systane - Dry Eye Syndromes | Phase 4 | Completed | Bp Consulting, Inc | 100 | 2008-02-01 | 2009-09-21 |
Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision
PEG-400, Systane - Myopia | Phase 4 | Completed | Bp Consulting, Inc | 40 | 2008-02-01 | 2008-11-24 |
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
Bromfenac, Ketorolac, Diclofenac - Acute Pseudophakic Cystoid Macular Edema | Phase 4 | Completed | Bp Consulting, Inc | 166 | 2008-01-01 | 2009-03-19 |
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination, dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination, brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy. - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Bp Consulting, Inc | 140 | 2005-01-01 | 2009-01-14 |
Conditions studied
Cataract (2) · Dry Eye Syndromes (2) · Glaucoma, Open-Angle (2) · Ocular Hypertension (2) · Myopia (1)
Interventions
bromfenac (5) · Brimonidine Tartrate (2) · Timolol (2) · prednisolone acetate (2) · Blinking (1) · Brimonidine Tartrate, Timolol Maleate Drug Combination (1) · Diclofenac (1) · Ketorolac (1) · Moxifloxacin (1) · Polyethylene Glycols (1) · dorzolamide (1) · dorzolamide-timolol combination (1) · nepafenac (1) · polyethylene glycol 400 (1)
Countries
United States (10) · Canada (1)
Top investigators
Barry Schechter, MD (1) · Chris Starr, MD (1) · Christopher Starr, MD (1) · David Rho, MD (1) · Eric Donnenfeld, MD (1) · James Gills, MD (1) · Jason Bacharach, M.D (1) · Nate Kleinfeldt, M.D (1)
Results publications
PMID 19476406